Scotch Plains, NJ, United States of America

Dennis M Zaller

This inventor holds 10 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: Csl Limited, Merck + Co., Inc.. Active years: 2001-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis M Zaller. Retrieved from https://idiyas.com/inventor/dennis-m-zaller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 188(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2001-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106617 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2018-10-23),

2. 9777062 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2017-10-03),

3. 9371388 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2016-06-21),

4. 8613925 - Anti-IL-13Rα1 antibodies and their uses thereof (2013-12-24),

5. 8568722 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2013-10-29),

6. 8207304 - Antibody antagonists of interleukin-13 receptor α1 (2012-06-26),

7. 7754213 - High affinity antibody antagonists of interleukin-13 receptor alpha 1 (2010-07-13),

8. 6498165 - Src kinase inhibitor compounds (2002-12-24),

9. 6329380 - SRC kinase inhibitor compounds (2001-12-11),

10. 6316444 - SRC kinase inhibitor compounds (2001-11-13),

Title: Dennis M Zaller: Innovator in Antibody Therapeutics

Introduction

Dennis M Zaller is a prominent inventor based in Scotch Plains, NJ (US), known for his significant contributions to the field of antibody therapeutics. With a total of 10 patents to his name, Zaller has made remarkable advancements in the treatment of conditions associated with interleukin-13 receptor alpha 1.

Latest Patents

Zaller's latest patents focus on high affinity antibody antagonists of interleukin-13 receptor alpha 1. These antibody molecules are effective in inhibiting IL-13Rα1-mediated activities, making them desirable antagonists for treating conditions linked to hIL-13Rα1 activity. The patents also disclose nucleic acids encoding these antibody molecules, vectors, host cells, and compositions that include the antibody molecules. Furthermore, methods for using these antibody molecules to inhibit or antagonize IL-13Rα1-mediated activities are also detailed in his patents.

Career Highlights

Throughout his career, Zaller has worked with notable companies such as CSL Limited and Merck & Company, Inc. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Zaller has collaborated with esteemed colleagues, including Andrew Donald Nash and Louis Jerry Fabri, further enhancing his work in the field of antibody therapeutics.

Conclusion

Dennis M Zaller's contributions to the field of antibody therapeutics through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.